• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高血压。与其他风险因素的关系。

Hypertension. Relationship with other risk factors.

作者信息

Kannel W B

出版信息

Drugs. 1986;31 Suppl 1:1-11. doi: 10.2165/00003495-198600311-00004.

DOI:10.2165/00003495-198600311-00004
PMID:3720567
Abstract

Elevated blood pressure is a major contributor to cardiovascular disease in general and to coronary heart disease in particular, now its most common sequela. The risk is proportional to the degree of blood pressure elevation, at all ages and in either sex, whether the increased pressure is labile or fixed, diastolic or systolic in character. The effect of blood pressure on cardiovascular disease incidence is independent of the influence of other predisposing co-factors, but the hazard is greatly influenced by them. Elevated pressures are often accompanied by hyperlipidaemia, hyperuricaemia, overweight, hyperglycaemia, elevated fibrinogen values and ECG abnormalities. The risk associated with any degree of elevation of pressure varies greatly, depending on the number and level of these often associated risk factors, and on whether or not there is the indication of target organ involvement. The excess cardiovascular risk in hypertensive persons tends to be concentrated in those with an increased LDL/HDL cholesterol ratio, impaired glucose tolerance, cigarette smokers and those with accompanying ECG abnormalities. Hypertension is best conceptualised as a component of a multivariate cardiovascular risk profile which provides a sound basis for determining urgency for drug treatment. Optimal preventive management of hypertension requires multifactorial correction of all disordered components of the cardiovascular risk profile before occurrence of target organ involvement.

摘要

一般而言,血压升高是心血管疾病的主要促成因素,尤其是冠心病的主要促成因素,而冠心病是目前最常见的后遗症。无论年龄大小、性别如何,无论血压升高是不稳定的还是固定的,是舒张期的还是收缩期的,风险都与血压升高的程度成正比。血压对心血管疾病发病率的影响独立于其他诱发共同因素的影响,但危害会受到这些因素的极大影响。血压升高常伴有高脂血症、高尿酸血症、超重、高血糖、纤维蛋白原值升高和心电图异常。与任何程度的血压升高相关的风险差异很大,这取决于这些常伴有的风险因素的数量和水平,以及是否有靶器官受累的迹象。高血压患者中额外的心血管风险往往集中在低密度脂蛋白/高密度脂蛋白胆固醇比值升高、糖耐量受损、吸烟者以及伴有心电图异常的人群中。最好将高血压理解为多变量心血管风险概况的一个组成部分,这为确定药物治疗的紧迫性提供了坚实的基础。高血压的最佳预防性管理需要在靶器官受累之前对心血管风险概况的所有紊乱成分进行多因素纠正。

相似文献

1
Hypertension. Relationship with other risk factors.高血压。与其他风险因素的关系。
Drugs. 1986;31 Suppl 1:1-11. doi: 10.2165/00003495-198600311-00004.
2
Hypertension as a risk factor for cardiac events--epidemiologic results of long-term studies.高血压作为心脏事件的危险因素——长期研究的流行病学结果
J Cardiovasc Pharmacol. 1993;21 Suppl 2:S27-37. doi: 10.1097/00005344-199321002-00006.
3
Influence of multiple risk factors on the hazard of hypertension.
J Cardiovasc Pharmacol. 1990;16 Suppl 5:S53-7.
4
Hypertension and other risk factors in coronary heart disease.
Am Heart J. 1987 Oct;114(4 Pt 2):918-25. doi: 10.1016/0002-8703(87)90588-6.
5
An integrated view of hypertension.高血压的综合观点。
J Hum Hypertens. 1989 Dec;3 Suppl 2:3-8.
6
Potency of vascular risk factors as the basis for antihypertensive therapy.
Eur Heart J. 1992 Dec;13 Suppl G:34-42. doi: 10.1093/eurheartj/13.suppl_g.34.
7
The clinical heterogeneity of hypertension.高血压的临床异质性。
Am J Hypertens. 1991 Mar;4(3 Pt 1):283-7. doi: 10.1093/ajh/4.3.283.
8
Risk factors in hypertension.高血压的危险因素。
J Cardiovasc Pharmacol. 1989;13 Suppl 1:S4-10. doi: 10.1097/00005344-198900131-00003.
9
The pathogenetic role and treatment of elderly hypertension.老年高血压的发病机制及治疗
Jpn Circ J. 1981 Jul;45(7):833-43. doi: 10.1253/jcj.45.833.
10
ESH-ESC guidelines for the management of hypertension.欧洲高血压学会(ESH)和欧洲心脏病学会(ESC)高血压管理指南
Herz. 2006 Jun;31(4):331-8. doi: 10.1007/s00059-006-2829-3.

引用本文的文献

1
Cohort Profile: The Framingham Heart Study (FHS): overview of milestones in cardiovascular epidemiology.队列简介:弗雷明汉心脏研究(FHS):心血管流行病学里程碑概述。
Int J Epidemiol. 2015 Dec;44(6):1800-13. doi: 10.1093/ije/dyv337.
2
The hypotensive effect of acute and chronic AMP-activated protein kinase activation in normal and hyperlipidemic mice.急性和慢性激活AMP活化蛋白激酶对正常及高脂血症小鼠的降压作用
Vascul Pharmacol. 2015 Nov;74:93-102. doi: 10.1016/j.vph.2015.07.010. Epub 2015 Jul 18.
3
Incentive spirometry for preventing pulmonary complications after coronary artery bypass graft.

本文引用的文献

1
Labile hypertension: a faulty concept? The Framingham study.
Circulation. 1980 Jun;61(6):1183-7. doi: 10.1161/01.cir.61.6.1183.
2
Perspectives on systolic hypertension. The Framingham study.收缩期高血压的观点。弗明汉姆研究。
Circulation. 1980 Jun;61(6):1179-82. doi: 10.1161/01.cir.61.6.1179.
3
Lipoproteins, cardiovascular disease, and death. The Framingham study.脂蛋白、心血管疾病与死亡。弗雷明汉姆研究
Arch Intern Med. 1981 Aug;141(9):1128-31.
激励性肺量计预防冠状动脉搭桥术后肺部并发症的研究
Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD004466. doi: 10.1002/14651858.CD004466.pub3.
4
Effect of terazosin on blood pressure and serum lipids.特拉唑嗪对血压和血脂的影响。
J Tongji Med Univ. 1999;19(4):291-4. doi: 10.1007/BF02886966.
5
[Process indicators and result indicators in the control of arterial hypertension].[动脉高血压控制中的过程指标和结果指标]
Aten Primaria. 2000 Dec;26(10):666-9. doi: 10.1016/s0212-6567(00)78748-8.
6
Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients.美托洛尔与卡维地洛对高血压患者血流动力学影响的比较。
Cardiovasc Drugs Ther. 1996 May;10(2):113-7. doi: 10.1007/BF00823588.
7
Community control of hypertension at work-site: epidemiological data of the Agusta project.
Eur J Epidemiol. 1995 Oct;11(5):591-5. doi: 10.1007/BF01719314.
8
A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease.塞利洛尔治疗心血管疾病的风险效益评估。
Drug Saf. 1994 Mar;10(3):220-32. doi: 10.2165/00002018-199410030-00004.
9
Goals of antihypertensive therapy.抗高血压治疗的目标。
Drugs. 1995 Feb;49(2):161-75. doi: 10.2165/00003495-199549020-00002.
10
Blood pressure profile in two adult male populations.两个成年男性群体的血压概况。
CMAJ. 1988 Sep 15;139(6):507-12.
4
Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study.收缩压、动脉僵硬度与中风风险。弗明汉姆研究。
JAMA. 1981 Mar 27;245(12):1225-9.
5
Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study.未识别心肌梗死的发病率和预后。弗雷明汉姆研究的最新情况。
N Engl J Med. 1984 Nov 1;311(18):1144-7. doi: 10.1056/NEJM198411013111802.
6
Interrelationship of sodium, volume, CNS, and hypertension.钠、血容量、中枢神经系统与高血压的相互关系。
Prog Biochem Pharmacol. 1983;19:208-29.
7
Role of nutrition in hypertension and its control--experimental aspects.营养在高血压及其控制中的作用——实验方面
Prog Biochem Pharmacol. 1983;19:177-91.
8
Manifestations of coronary disease predisposing to stroke. The Framingham study.易引发中风的冠心病表现。弗雷明汉姆研究。
JAMA. 1983 Dec 2;250(21):2942-6.
9
Epidemiology of hypertension.高血压流行病学
Med Clin North Am. 1977 May;61(3):467-86. doi: 10.1016/s0025-7125(16)31311-6.
10
Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study.
Ann Intern Med. 1979 Jan;90(1):85-91. doi: 10.7326/0003-4819-90-1-85.